Drug interactions
Bosentan + Irinotecan liposomal
Severity: Moderate
Bosentan and Irinotecan liposomal: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
CYP3A4 inducers can lower exposure to irinotecan's active metabolite SN-38 and reduce efficacy. Bosentan is a moderate inducer, so the effect is likely smaller than with strong inducers.
What this interaction means in plain words
Bosentan and Irinotecan liposomal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Bosentan induces CYP3A4, increasing conversion of irinotecan to inactive metabolites and lowering SN-38 exposure.
What to do
Avoid strong CYP3A4 inducers and monitor for reduced tumor response with bosentan. Consider an alternative pulmonary hypertension agent if feasible.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Irinotecan liposomal, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Bosentan
- Bosentan + Cyclosporin Contraindicated
- Bosentan + Glibenclamide Contraindicated
- Bosentan + Glyburide-metformin Contraindicated
- Bosentan + Lonafarnib Contraindicated
- Bosentan + Sparsentan Contraindicated
- Artemether / lumefantrine + Bosentan Major
Frequently asked questions
Can I take Bosentan with Irinotecan liposomal?
MediHelp rates the interaction as moderate. Bosentan and Irinotecan liposomal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. CYP3A4 inducers can lower exposure to irinotecan's active metabolite SN-38 and reduce efficacy. Bosentan is a moderate inducer, so the effect is likely smaller than with strong inducers.
How serious is the interaction between Bosentan and Irinotecan liposomal?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid strong CYP3A4 inducers and monitor for reduced tumor response with bosentan. Consider an alternative pulmonary hypertension agent if feasible.
What other medicines interact with Bosentan?
MediHelp also lists interactions of Bosentan with, for example, Cyclosporin, Glibenclamide, Glyburide-metformin. The full list is on the Bosentan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
